Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Surgical Science Sweden AB's Beta is 1.8272.
Surgical Science Sweden AB (FRA:4P41) Beta Explanation
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Surgical Science Sweden AB's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Science Sweden AB Beta vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgical Science Sweden AB's Beta distribution charts can be found below:
* The bar in red indicates where Surgical Science Sweden AB's Beta falls into.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
Surgical Science Sweden AB (FRA:4P41) has a Beta of 1.8272 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Surgical Science Sweden AB and its competitors.
Is Surgical Science Sweden AB's Beta too high?
Surgical Science Sweden AB's current Beta is 1.8272. Overall, Surgical Science Sweden AB has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's Beta compare to VEEV and BTSG?
Surgical Science Sweden AB's Beta of 1.8272 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Healthcare Providers & Services company?
A good Beta depends on the Healthcare Providers & Services industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Surgical Science Sweden AB and its competitors. Surgical Science Sweden AB's current Beta is 1.8272. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Surgical Science Sweden AB (FRA:4P41) is currently considered Significantly Undervalued. The stock's GF Value™ is €13.83, compared to a current price of €2.72 — trading 80.3% below its estimated fair value. The current Beta is 1.8272. Surgical Science Sweden AB's overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Surgical Science Sweden AB (FRA:4P41), the current Beta is 1.8272 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (FRA:4P41) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of €2.72 is trading 80.3% below its estimated GF Value™ of €13.83.
GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.
Key valuation signals for FRA:4P41:
Beta: 1.8272
GF Value™: €13.83 vs. price of €2.72 (80.3% below fair value)
No single metric tells the full story. See the FRA:4P41 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
86GF Score
Get the complete analysis for FRA:4P41
Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4P41 has been successfully added to your 
